These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 20704685)
21. Nestin is expressed in HMB-45 negative melanoma cells in dermal parts of nodular melanoma. Kanoh M; Amoh Y; Tanabe K; Maejima H; Takasu H; Katsuoka K J Dermatol; 2010 Jun; 37(6):505-11. PubMed ID: 20536663 [TBL] [Abstract][Full Text] [Related]
22. Markers of melanocytic tumour progression. Ruiter DJ; van Muijen GN J Pathol; 1998 Dec; 186(4):340-2. PubMed ID: 10209480 [TBL] [Abstract][Full Text] [Related]
23. Expression of the stem cell marker nestin in peripheral blood of patients with melanoma. Fusi A; Ochsenreither S; Busse A; Rietz A; Keilholz U Br J Dermatol; 2010 Jul; 163(1):107-14. PubMed ID: 20346020 [TBL] [Abstract][Full Text] [Related]
24. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711 [TBL] [Abstract][Full Text] [Related]
25. Melanoma progression in a changing environment. van Kempen LC; van Muijen GN; Ruiter DJ Eur J Cell Biol; 2007 Feb; 86(2):65-7. PubMed ID: 17241688 [No Abstract] [Full Text] [Related]
26. Melanoma gene expression and clinical course. Vourc'h-Jourdain M; Volteau C; Nguyen JM; Khammari A; Dreno B Arch Dermatol Res; 2009 Oct; 301(9):673-9. PubMed ID: 19326132 [TBL] [Abstract][Full Text] [Related]
29. Correlation of subjective self-reported melanoma growth rate with objective tumor proliferation markers. Liu W; McArthur GA; Trivett M; Murray WK; Wolfe R; Kelly JW Arch Dermatol; 2008 Apr; 144(4):555-6. PubMed ID: 18427059 [No Abstract] [Full Text] [Related]
30. Diffuse cutaneous melanosis in malignant melanoma. Paulo Filho Tde A; da Trindade Neto PB; Reis JC; Bartelt L; da Costa SA Dermatol Online J; 2007 May; 13(2):9. PubMed ID: 17498428 [No Abstract] [Full Text] [Related]
31. MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Roeder C; Schuler-Thurner B; Berchtold S; Vieth G; Driesch Pv; Schuler G; Lüftl M Arch Dermatol Res; 2005 Jan; 296(7):314-9. PubMed ID: 15570431 [TBL] [Abstract][Full Text] [Related]
32. The pathogenic role of growth factors in melanoma. Richmond A Semin Dermatol; 1991 Sep; 10(3):246-55. PubMed ID: 1931574 [TBL] [Abstract][Full Text] [Related]
34. PUMA expression is significantly reduced in human cutaneous melanomas. Karst AM; Dai DL; Martinka M; Li G Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057 [TBL] [Abstract][Full Text] [Related]
35. Cancer stem cells: Invitation to a second round. Dirks P Nature; 2010 Jul; 466(7302):40-1. PubMed ID: 20596007 [No Abstract] [Full Text] [Related]
36. Loss of primary cilia in melanoma cells is likely independent of proliferation and cell cycle progression. Snedecor ER; Sung CC; Moncayo A; Rothstein BE; Mockler DC; Tonnesen MG; Jones EC; Fujita M; Clark RA; Shroyer KR; Chen J J Invest Dermatol; 2015 May; 135(5):1456-1458. PubMed ID: 25629424 [No Abstract] [Full Text] [Related]
37. A fitness model for melanoma-initiating cells. Kubick BJ; Roop DR Pigment Cell Melanoma Res; 2011 Jun; 24(3):396-7. PubMed ID: 22489315 [No Abstract] [Full Text] [Related]
38. The great escape: another way for melanoma to leave physiological control? Smalley KS; Herlyn M J Invest Dermatol; 2003 Oct; 121(4):xi-xii. PubMed ID: 14632176 [No Abstract] [Full Text] [Related]
39. Role of apaf-1 in melanoma drug resistance and apoptosis. Röckmann H; Schadendorf D J Invest Dermatol; 2005 Aug; 125(2):386-7. PubMed ID: 16098052 [No Abstract] [Full Text] [Related]